Small Molecules
10 January 2013
InSite Vision Completes Phase 3 Clinical Study of BromSite for the Reduction of Pain and Inflammation After Cataract Surgery10 January 2013
Ultragenyx Announces In-Licensing of Clinical-Stage Product Triheptanoin for Treatment of Long-Chain Fatty Acid Oxidation Disorders9 January 2013
Cell Therapeutics Begins Enrollment in Phase 3 PERSIST-1 Trial of Pacritinib for the Treatment of Myelofibrosis9 January 2013
The Medicines Company Announces Positive Results in a Phase 3 Trial of Cangrelor in the Treatment of Patients Undergoing PCI9 January 2013
Theravance and Alfa Wassermann Announce Initiation of Phase 2 Study With Velusetrag for Gastroparesis8 January 2013
Edison Pharmaceuticals Announces Initiation of EPI-743 Phase 2B Friedreich’s Ataxia Clinical Trial8 January 2013
Addex Announces Positive Data with ADX71441 in a Pre-Clinical Transgenic Model of Charcot-Marie-Tooth 1A Disease8 January 2013
Esperion Announces Positive Topline Results from a Phase 2 Clinical Trial of ETC-1002 in Patients with Type 2 Diabetes8 January 2013
ChemoCentryx Advances a New Generation CCR9 Inhibitor, CCX507, Into Clinical Development8 January 2013
First Patient Enrolled in Hanmi’s Phase 1b/IIa Clinical Trial in Korea, using KX01/Paclitaxel Combination8 January 2013
Telormedix granted IND for Phase II in bladder cancer8 January 2013
Merck Announces FDA Acceptance of Resubmission of New Drug Application for Sugammadex Sodium Injection7 January 2013
Boehringer Ingelheim and Eli Lilly and Company announce positive top-line pivotal Phase III data results for empagliflozin7 January 2013
Apremilast ESTEEM Program Meets Primary and Major Secondary Endpoint in Pivotal Phase III Psoriasis Trials4 January 2013
Radius Completes Enrollment for Phase 2 Study of BA058-Transdermal Patch for Treatment of Postmenopausal Osteoporosis4 January 2013
MediciNova Provides Development Update3 January 2013
Merck Announces FDA Acknowledgement of Resubmission of New Drug Application for Ezetimibe/Atorvastatin Tablets3 January 2013
Repros’ Proellex(R)-V Topline Analysis Suggests 12 Mg Dose Effective and Well Tolerated in Phase 2 for Uterine FibroidsNews Channels
Newsletter
La Merie Biologics
La Merie Publishing releases a weekly newsletter with a focus on biopharmaceutical research and development.
Subscribe
Newsletter
New Product Alert
La Merie Publishing offers an e-mail notification service about the release of new products of La Merie Publishing. This New Product Release Alert also informs about the release of FREE reports produced by La Merie Publishing.
Subscribe
Featured reports